Affiliated with a Castle Connolly Top Hospital
Who is Dr. Medeiros, Hematologist in Stanford, CA?
Dr. Bruno Medeiros, MD is a Hematologist, who primarily practices in Stanford, CA with 2 additional practice locations. He is board certified. Dr. Medeiros graduated from Federal University of Parana and completed his residency at University of Colorado Health Science Center. Dr. Medeiros is fluent in English and Portuguese, and is currently seeing new patients. Dr. Medeiros’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Medeiros’s office at (650) 723-4000.
Where did Dr. Medeiros go to medical school and complete their residency?
Fellowship: Acute leukemia, Princess Margaret Hospital - University of Toronto | University of Colorado Health Science Center CO | Acute leukemia, Princess Margaret Hospital - University of Toronto
Residency: University of Colorado Health Science Center | University of Colorado Denver Affiliated Hospitals
Medical School: Federal University of Parana
Is Dr. Medeiros board certified as a Hematologist?
Yes, Dr. Bruno Medeiros, MD is board certified by the American Board of Internal Medicine since 2006, American Board of Internal Medicine since 2005
What languages does Dr. Medeiros speak?
Dr. Medeiros and their clinical team can communicate with patients in the following languages:
English
Portuguese
What conditions does a Hematologist like Dr. Medeiros typically treat?
As a Hematologist, Dr. Medeiros diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Medeiros. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Chronic Myeloid Leukemia
- Acute Lymphocytic Leukemia in Remission
- Chronic Myelogenous Leukemia Treatment (PDQ®)
- Acute Lymphocytic Leukemia
- CML
- Chronic myelogenous leukemia
- Philadelphia chromosome positive leukemia
- ALL Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Childhood Leukemia in Remission
ICD-10 Codes:
- C9210: Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
- C9101: Acute lymphoblastic leukemia, in remission
Also known as:
- Multiple Myeloma
- Multiple Myeloma in Remission
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ)
- Active multiple myeloma
- Untreated multiple myeloma
- Plasma cell myeloma
- Plasma Cell Myeloma in Remission
- Kahler's Disease in Remission
- Myeloma in Remission
ICD-10 Codes:
- C9000: Multiple myeloma not having achieved remission
- C9001: Multiple myeloma in remission
What procedures does a Hematologist like Dr. Medeiros typically perform?
As a Hematologist, Dr. Medeiros performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Medeiros. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Does Dr. Medeiros accept my insurance?
Dr. Medeiros accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Medeiros accept in Stanford, CA?
Dr. Medeiros in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Advantage
All Other Third Party
Care N' Care Insurance Company
CVS Health (formerly Aetna)
Humana
Medicaid
Medicare
Santa Cruz County
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Medeiros' office located?
Recognitions
Publications
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators
, 2014
Unsuccessful diagnostic cytogenetic alysis is a poor prognostic feature in acute myeloid leukaemia
, 2014
Sequential azacitidine plus lelidomide combition
, 2013
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia
, 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lelidomide for
, 2012
Tailored temozolomide therapy according to MGMT methylation status
, 2012
Cytarabine Dose for Acute Myeloid Leukemia
, 2011
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .
, 2014
Gemtuzumab ozogamicin in combition with vorinostat
, 2014
Hematopoietic Stem Cell Transplantation for Hematologic Maligncies in Older Adults
, 2014
Qualitative alysis of practicing oncologists' attitudes
, 2013
A single-center experience of the tionwide daunorubicin shortage
, 2013
Amrubicin, a Novel Investigatiol Anthracycline
A Phase I/II Study of Bortezomib
Hemophagocytic lymphohistiocytosis in pregncy: a case report and review of treatment options
, 2012
Waldenstrom's Macroglobulinemia
, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
, 2012
Absolute lymphocyte count at day 28 independently predicts event-free
, 2012
Novel agents in acute myeloid leukemia
, 2012
New treatment approaches for older adults with multiple myeloma
, 2012
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post
, 2012
Senior Adult Oncology
, 2012
Phase I trial of a novel human monoclol antibody mAb216 in patients with relapsed or refractory B
, 2012
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
, 2012
Multiple Myeloma
, 2011
Acute myeloid leukaemia in the elderly: a review
, 2011
Microfluidic purification and alysis of hematopoietic stem cells from bone marrow
, 2011
A Phase I Study of Sequential Azacitidine
, 2010
Second-line mitoxantrone, etoposide
, 2010
Plasma cell leukemia: concepts and magement.
, 2010
Plasma cell leukemia: concepts and magement
, 2010
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with
, 2010
PHASE 2 TRIAL OF VORINOSTAT
, 2010
Multiple Myeloma
, 2009
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia
, 2009
NCCN clinical practice guidelines in oncology: multiple myeloma.
, 2009
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
, 2009
Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia
, 2009
Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia
, 2009
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin
, 2009
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators
, 2014
Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature
, 2014
Sequential azacitidine plus lenalidomide combination
, 2013
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia
, 2012
Blood consult: monosomal karyotype acute myeloid leukemia
, 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide
, 2012
Impact of residual normal metaphases in core binding factor acute myeloid leukemia
, 2012
Unveiling the complexity of CK+ AML.
, 2012
Tailored temozolomide therapy according to MGMT methylation status
, 2012
Cytarabine Dose for Acute Myeloid Leukemia
, 2011
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia
, 2010
Mcl-1 dependence predicts response to vorinostat
, 2014
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .
, 2014
Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia.
, 2014
Gemtuzumab ozogamicin in combination with vorinostat
, 2014
Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults
, 2014
Qualitative analysis of practicing oncologists' attitudes
, 2013
A single-center experience of the nationwide daunorubicin shortage
, 2013
CD11b expression and MK+ AML: A sign of impending doom?
, 2013
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia
, 2013
CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells
, 2012
Amrubicin, a Novel Investigational Anthracycline
Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine
A Phase I/II Study of Bortezomib
Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options
, 2012
Waldenstrom's Macroglobulinemia
, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
, 2012
Absolute lymphocyte count at day 28 independently predicts event-free
, 2012
Novel agents in acute myeloid leukemia
, 2012
New treatment approaches for older adults with multiple myeloma
, 2012
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post
, 2012
Aggressive EBV-associated Lymphoproliferative Disorder
, 2012
Senior Adult Oncology
, 2012
It doesn't matter if you're black or white, does it?
, 2012
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B
, 2012
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
, 2012
Phase 2 Trial of G-CSF Priming, Clofarabine
, 2011
Multiple Myeloma
, 2011
Unfavorable-risk cytogenetics in acute myeloid leukemia
, 2011
Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer
, 2011
Acute myeloid leukaemia in the elderly: a review
, 2011
Microfluidic purification and analysis of hematopoietic stem cells from bone marrow
, 2011
A Phase I Study of Sequential Azacitidine
, 2010
Temozolomide In Acute Myeloid Leukemia
, 2010
Second-line mitoxantrone, etoposide
, 2010
Plasma cell leukemia: concepts and management.
, 2010
Plasma cell leukemia: concepts and management
, 2010
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with
, 2010
PHASE 2 TRIAL OF VORINOSTAT
, 2010
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
, 2010
Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
, 2009
Is Time of the Essence in Adult Acute Myeloid Leukemia
, 2009
Multiple Myeloma
, 2009
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia
, 2009
NCCN clinical practice guidelines in oncology: multiple myeloma.
, 2009
Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
, 2009
Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia
, 2009
Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia
, 2009
Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study
, 2009
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin
, 2009
What is Dr. Medeiros's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Medeiros's National Provider Identifier (NPI) number is 1760420657.
What common questions do patients ask about Dr. Medeiros?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Medeiros
What is Dr. Bruno Medeiros's specialty?
Dr. Medeiros is a Hematologist near Stanford, CA.
What does a Hematologist do?
An internist with advanced training specializing in disorders of the blood, spleen, and lymphatic system. This specialist manages conditions such as anemia, clotting disorders, sickle cell disease, hemophilia, leukemia, and lymphoma.
Is this Dr. Bruno Medeiros affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Medeiros is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Hematologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Hematologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Bruno Medeiros accepting new patients in Stanford, CA?
Yes, Dr. Bruno Medeiros is accepting new patients at this time.
Does Dr. Bruno Medeiros offer online booking?
Please contact Dr. Medeiros's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Bruno Medeiros?
Please contact Dr. Medeiros's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Bruno Medeiros have?
Dr. Bruno Medeiros is certified by the American Board of Internal Medicine.
Other Hematologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients